EXHIBIT 99.1





CEL-SCI CORPORATION                                             NEWS

8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
 www.cel-sci.com                                         (703) 506-9460

             CEL-SCI Corporation Announces Proposed Public Offering
                          of Common Stock and Warrants

Vienna, VA, December 18, 2013 - CEL-SCI Corporation (NYSE MKT: CVM), a
late-stage oncology company, today announced that it intends to offer and sell
common stock and warrants in an underwritten public offering. The offering is
subject to market conditions, and there can be no assurance as to whether or
when the offering may be completed.

Laidlaw & Company  (UK) Ltd.  is acting as sole  book-running  manager for the
offering.   Dawson  James  Securities,  Inc. is acting as  co-manager  for the
offering.

A shelf registration statement and accompanying base prospectus on Form S-3
relating to the securities was filed with the Securities and Exchange Commission
and is effective. A preliminary prospectus supplement relating to the offering
has been filed with the SEC and is available on the SEC's web site at
http://www.sec.gov. Copies of the final prospectus supplement relating to the
offering, when available, may be obtained from the offices of Laidlaw & Company
(UK) Ltd., 546 Fifth Avenue, 23rd Floor, New York, NY, 10036, telephone:
212-953-4900., or from the above-mentioned SEC website.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws
of any such jurisdiction.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the
treatment of cancer and other diseases by utilizing the immune system, the
body's natural defense system. The lead investigational therapy is Multikine
(Leukocyte Interleukin, Injection), currently being studied in a pivotal global
Phase III clinical trial. CEL-SCI is also investigating a different
peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1
hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis
(currently in preclinical testing) using its LEAPS technology platform. The
investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing
regions of H1N1 Pandemic Flu (See Journal of Clinical Investigation - J Clin
Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550) Avian Flu (H5N1), and the
Spanish Flu, as CEL-SCI scientists are very concerned about the possible
emergence of a new more virulent hybrid virus through the combination of H1N1
and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna,
Virginia, and in/near Baltimore, Maryland.



Multikine is the trademark that CEL-SCI has registered for this investigational
therapy, and this proprietary name is subject to FDA review in connection with
its future anticipated regulatory submission for approval.

When used in this release, the words "intends," "believes," "anticipated" and
"expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective, receiving
necessary regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10-K for the year ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.